Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02525263 · ClinicalTrials.gov registry record · Phase 2
Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)
A Phase 2 study, sponsored by Prokidney.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02525263: Clinical Trial Phase 2 study, sponsored by Prokidney.
NCT02525263 is a Phase 2 study that was terminated before completion, run by Prokidney. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02525263, a Phase 2 study, was terminated before completion, sponsored by Prokidney.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
A Phase II, Open-Label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (RMTX-CL001). NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. All enrolled subjects will be treated with up to two injections of NKA at least 6 months apart.
Primary Outcome
Procedure and/or product related adverse events (AE's) through 12 months following the final NKA implantation, as measured by AE reporting.
Interventions
- BIOLOGICAL Neo-Kidney Augment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-08 |
| Phase | Phase 2 |
Why NCT02525263 stopped before completion
NCT02525263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Neo-Kidney Augment is the first listed.
NCT02525263 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02525263 about?
NCT02525263 is a clinical study titled "Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)". A Phase II, Open-Label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (RMTX-CL001). NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. All enrolled subjects will b...
What is the current status of trial NCT02525263?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-07. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02525263?
The interventions under investigation include: Neo-Kidney Augment (BIOLOGICAL).
Who is sponsoring clinical trial NCT02525263?
This trial is sponsored by Prokidney, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02525263's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia